开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Melissa Stockton-Brown
Parkinson’s Disease (PD) is the second most common neurodegenerative disease in the United States, effecting approximately a million Americans every year. Though the disease is not fatal, it puts patients at risk for other causes of morbidity and mortality (example: falls, aspiration, serious infections). Along with classic psychiatric and motor symptoms reported by Parkinson’s patients, fatigue is a common and disabling problem. Medical treatment for fatigue in PD is typically managed non-medically through lifestyle modifications (example: sleep hygiene, daytime naps, exercise) though medications may also be used (example: antidepressants, stimulants). Medications may come with side effects; at this point there is no satisfactory treatment specifically targeted at fatigue in PD.